Harvard Eye Associates

1. Novartis Pharmaceuticals Corporation $276,676 5 payments
2. Allergan Inc. $275,000 1 payment
3. Sight Sciences, Inc. $109,110 10 payments
4. Alcon Research LLC $69,189 131 payments
5. AbbVie, Inc. $57,407 2 payments
6. Aerie Pharmaceuticals, Inc. $55,896 15 payments
7. Astellas Pharma Global Development $29,813 13 payments
8. ANI Pharmaceuticals, Inc. $15,984 1 payment
9. Glaukos Corporation $10,736 5 payments
10. EyePoint Pharmaceuticals US, Inc. $9,840 1 payment

1. A Randomized, Placebo-Controlled, Double-Masked, Multi-Center, Dose-Ranging Study to Evaluate the Safety, and Efficacy of Unr844 in Subjects With Presbyopia $143,629 2 payments
2. The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (Clear) Study: An Investigation of Lifitegrast's Speed of Onset in Improving Ocular Surface Health in Dry Eye Patients in the Cataract Population. $110,708 1 payment
3. Randomized Controlled Trial to Evaluate the Safety and Effectiveness of the TearCare System in the Treatment of the Signs and Symptoms of Dry Eye Disease $74,740 6 payments
4. Retrospective Study of the Effectiveness and Safety of Bimatoprost Implant in Real World Clinical Setting in the US $57,407 2 payments
5. Post Approval Study of the AcrySof IQ ReSTOR Toric IOL $50,087 94 payments
6. A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy (Fuchs) $34,930 11 payments
7. Prospective Randomized Masked Controlled Trial to Evaluate the Safety and Effectiveness of the TearCare System in the Treatment of the Signs and Symptoms of Dry Eye Disease (SAHARA) $34,370 4 payments
8. A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration $29,813 13 payments
9. A Randomized, Double-Masked, Multicenter Study to Evaluate the Safety and Efficacy of Ecf843 VS Vehicle in Subjects With Dry Eye Disease $22,339 2 payments
10. A Multicenter, Open-Label Study of Rhopressa (Netarsudil Ophthalmic Solution) 0.02% for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma Or Ocular Hypertension in A Real-World Setting $20,966 4 payments

1. Other $6,601 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.